全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Management of High Blood Pressure in Those without Overt Cardiovascular Disease Utilising Absolute Risk Scores

DOI: 10.4061/2011/595791

Full-Text   Cite this paper   Add to My Lib

Abstract:

Increasing blood pressure has a continuum of adverse risk for cardiovascular events. Traditionally this single measure was used to determine who to treat and how vigorously. However, estimating absolute risk rather than measurement of a single risk factor such as blood pressure is a superior method to identify who is most at risk of having an adverse cardiovascular event such as stroke or myocardial infarction, and therefore who would most likely benefit from therapeutic intervention. Cardiovascular disease (CVD) risk calculators must be used to estimate absolute risk in those without overt CVD as physician estimation is unreliable. Incorporation into usual practice and limitations of the strategy are discussed. 1. Introduction Physicians treat diseases. For this reason when increasing blood pressure was recognized as a risk factor for coronary artery disease and stroke, it was dichotomized into a disease state “hypertension” and a nondisease state “normotension” by creating an arbitrary cut point. This cut point has generally become lower over time as evidence of benefit in treating blood pressure levels lower than the contemporary accepted cut points accumulated. Recognition of other risk factors such as dyslipidemia, higher risk groups such as the aged [1, 2], and those with comorbid conditions such as diabetes [3] has led to differential treatment thresholds and target blood pressures resulting in confusing or conflicting guideline recommendations, depending on which peak body produced them. Is there a simpler way to identify those most likely to have a major adverse cardiovascular event who do not have overt disease, and therefore who needs rigorous therapeutic intervention for their blood pressure and other CVD risk factors? 2. Absolute Cardiovascular Risk Increasing blood pressure has a log-linear relationship with adverse risk for cardiovascular events [4]. Using this figure alone in clinical decision making risks overtreatment (“medicalization” where medication adverse events likely to exceed benefit, and adverse cost-effectiveness) and undertreatment (failure to act where medication benefit is likely to exceed adverse events and be cost effective). Estimating absolute risk, the risk of having an adverse cardiovascular event over a specified period of time (usually 5 or 10 years), is a superior method to measurement of blood pressure alone to identify who is most at risk of having a cardiovascular event and therefore who would most likely benefit from intervention [5, 6]. It does this because the figure derived is more holistic, incorporating

References

[1]  N. M. Kaplan, “Systolic hypertension in the elderly program (SHEP) and swedish trial in old patients with hypertension (STOP). the promises and the potential problems,” American Journal of Hypertension, vol. 5, no. 5, part 1, pp. 331–334, 1992.
[2]  SHEP Cooperative Research Group, “Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension,” The Journal of the American Medical Association, vol. 265, no. 24, pp. 3255–3264, 1991.
[3]  S. M. Haffner, S. Lehto, T. R?nnemaa, K. Py?r?l?, and M. Laakso, “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,” The New England Journal of Medicine, vol. 339, no. 4, pp. 229–234, 1998.
[4]  S. Macmahon, R. Peto, J. Cutler et al., “Blood pressure, stroke, and coronary heart disease. part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias,” The Lancet, vol. 335, no. 8692, pp. 765–774, 1990.
[5]  R. Jackson, “Guidelines on preventing cardiovascular disease in clinical practice,” British Medical Journal, vol. 320, no. 7236, pp. 659–661, 2000.
[6]  S. Baker, P. Priest, and R. Jackson, “Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated,” British Medical Journal, vol. 320, no. 7236, pp. 680–685, 2000.
[7]  Guidelines Committee, “European society of hypertension-european society of cardiology guidelines for the management of arterial hypertension,” Journal of Hypertension, vol. 21, no. 6, pp. 1011–1053, 2003.
[8]  A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report,” Journal of the American Medical Association, vol. 289, no. 19, pp. 2560–2572, 2003.
[9]  British Cardiac Society , British Hypertension Society, Diabetes UK, Heart UK, Primary Care Cardiovascular Society, and Stroke Association, “JBS 2: joint British societies' guidelines on prevention of cardiovascular disease in clinical practice,” Heart Journal, vol. 91, supplement 5, pp. 1–52, 2005.
[10]  National Heart foundation of Australia (national blood pressure and vascular disease advisory committee), Guide to management of hypertension, 2008.
[11]  National Vascular Disease Alliance, “Guidelines for the assessment of absolute cardiovascular disease risk,” 2009.
[12]  Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice, “European guidelines on cardiovascular disease prevention in clinical practice,” European Heart Journal, vol. 24, no. 17, pp. 1601–1610, 2003.
[13]  R. B. D'Agostino, R. S. Vasan, M. J. Pencina et al., “General cardiovascular risk profile for use in primary care: the Framingham heart study,” Circulation, vol. 117, no. 6, pp. 743–753, 2008.
[14]  K. M. Anderson, P. M. Odell, P. W. Wilson, and W. B. Kannel, “Cardiovascular disease risk profiles,” American Heart Journal, vol. 121, no. 1, part 2, pp. 293–298, 1991.
[15]  A. Peeters, J. Ting, M. Nelson, and J. J. McNeil, “Coronary heart disease risk prediction by general practitioners in Victoria,” Medical Journal of Australia, vol. 180, no. 5, p. 252, 2004.
[16]  S. J. Pocock, V. McCormack, F. Gueyffier, F. Boutitie, R. H. Fagard, and J. P. A. Boissel, “A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials,” British Medical Journal, vol. 323, no. 7304, pp. 75–81, 2001.
[17]  M. R. Nelson, P. Ryan, A. M. Tonkin, et al., “Prediction of cardiovascular events in subjects in the second Australian national blood pressure study,” Hypertension, vol. 56, no. 1, pp. 44–48, 2010.
[18]  Z. Wang and W. E. Hoy, “Is the Framingham coronary heart disease absolute risk function applicable to aboriginal people?” Medical Journal of Australia, vol. 182, no. 2, pp. 66–69, 2005.
[19]  S. Yusuf, P. Sleight, J. Pogue, et al., “Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients,” The New England Journal of Medicine, vol. 342, no. 3, pp. 145–153, 2000.
[20]  E. B. J. Lonn, K. K. Teo, P. Pais, D. Xavier, and S. Yusuf, “The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions,” Circulation, vol. 122, no. 20, pp. 2087–2088, 2010.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133